Anika Therapeutics Inc (ANIK) Dividend History

Company News

• Anika Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

  Anika Therapeutics, Inc. granted non-statutory stock options covering 2,500 shares of common stock to a newly hired non-executive employee. The options will vest over three years and are subject to the terms of the company's 2021 Inducement Plan.

  GlobeNewswire Inc.
• Anika Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

  Anika Therapeutics, a global leader in osteoarthritis pain management and regenerative solutions, announced the grant of 5,000 stock options to two newly hired non-executive employees. The options were granted as a material inducement to the grantees' acceptance of employment with Anika.

  GlobeNewswire Inc.
• Anika Completes Divestiture of Parcus Medical

  Anika Therapeutics announced the completion of the divestiture of its Parcus Medical business, allowing the company to focus on its core hyaluronic acid technology and growing Regenerative Solutions portfolio.

  GlobeNewswire Inc.
• Osteoarthritis Therapeutics Market Size to Reach USD 24.34 Bn by 2034

  The global osteoarthritis therapeutics market is expected to grow from USD 9.91 billion in 2024 to USD 24.34 billion by 2034, driven by the rising prevalence of osteoarthritis and technological advancements in surgical treatments. Europe and Asia Pacific are the key regional markets.

  GlobeNewswire Inc.

  Featured Companies: ABT BVS JNJ REGN
• Anika Announces Third Quarter 2024 Results Conference Call Date

  Anika Therapeutics, a global joint preservation company, announced that it will report its Q3 2024 financial results and host a conference call on October 31, 2024.

  GlobeNewswire Inc.